Operates a chain of multi-specialty hospitals across western and central India — Thane, Pune, Indore and the newly commissioned Dombivli — earning ₹1,499.8 crore in FY26 (+15.2% YoY). The Dombivli greenfield (500-bed capacity with 300 beds currently fitted out across 750,000 sq ft) opened in February 2026 two months ahead of schedule, and a 400-bed quaternary-care hospital is being set up on a one-lakh-sq-ft site in BKC Mumbai, with further projects in the pipeline at Pune South, Mira Road and Thane, taking the long-term bed-count target to roughly 3,000. Revenue is driven by inpatient and outpatient volumes — 10.8 lakh volumes in FY26, with Average Revenue Per Occupied Bed at ₹67,700 and Average Length of Stay of 3.87 days; insurance payers contributed 55.4% of FY26 revenue and government schemes 1%. The model is asset-heavy and expansion-driven: FY26 capex was deployed across Dombivli, BKC land, Pune and Mira Road, with gross debt at ~₹500 crore against cash of ~₹545 crore, leaving the balance sheet net cash positive. Other operating expenses (40.9% of revenue) and employee costs (17.1%) are the largest cost lines, followed by depreciation at 5.8%. A subsidiary has separately acquired Sulcus Private Limited to set up an IV fluids and pharmaceutical manufacturing facility near Ujjain with ₹35–40 crore of further investment planned. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Hospital services — insurance payers, Hospital services — self-pay and corporate patients, Hospital services — government schemes. Asset-heavy, owned-infrastructure multi-specialty hospital chain in active greenfield expansion.
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,070 | 1,262 | 1,500 |
| EBITDA (ex other income) | 238 | 297 | 343 |
| margin % | 22.3 | 23.5 | 22.9 |
| Owners' profit | 0 | 193 | 194 |
| EPS, as reported (₹) | 28.65 | 29.47 | 29.59 |
| ROE % · ROCE % | 15.1 · 18.9 | 14.3 · 15.3 | 12.9 · 13.8 |
| Debt / equity (x) | 0.00 | 0.24 | 0.33 |
| Cash from operations | 115 | 253 | 268 |
| Capex | (85) | (321) | (502) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 323 | 321 | 327 | 348 | 394 | 365 | 388 | 411 |
| Profit before tax | 69 | 67 | 62 | 62 | 74 | 57 | 66 | 51 |
| Net profit | 52 | 53 | 45 | 44 | 57 | 42 | 49 | 38 |
| EPS (₹) | 7.86 | 8.01 | 6.84 | 6.69 | 8.75 | 6.49 | 7.66 | 5.72 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| APOLLO HOSPITALS ENTER. L | 1,27,062 | 60.8 | 12.74 | 33.5 | 20.1 | 16.6 | 19.0 | 16.2 |
| MAX HEALTHCARE INS LTD | 1,00,993 | 69.2 | 9.40 | 44.0 | 13.4 | 11.1 | 27.3 | 27.0 |
| FORTIS HEALTHCARE LTD | 67,025 | 64.0 | 6.59 | 32.9 | 10.5 | 9.7 | 17.8 | 22.0 |
| ASTER DM QUALITY CARE LTD | 39,689 | 124.0 | 8.21 | 40.4 | 8.8 | 8.5 | (11.6) |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Aug 2026 · Q1 FY27: revenue 411cr, EBITDA 19.3%, Dombivli drags 9.5cr | investor communications | medium | — | — |
| 3 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| 3 Aug 2026 · Audio link of Q1 FY27 analyst and investor conference call shared | investor communications | medium | — | — |
| 31 Jul 2026 · Board authorizes CFO along with MD for materiality determinations | compliance | minimal | — | — |
| 31 Jul 2026 · Jupiter Hospitals Q1FY27: PAT falls 15% as new hospital drags margins | investor communications | medium | — | — |
| 31 Jul 2026 · Q1 results, new CFO appointed, subsidiary acquires Sulcus Pharma | management changes | high | — | — |
| 31 Jul 2026 · Jupiter Hospitals Q1 results, new CFO, subsidiary acquires Sulcus | management changes | high | — | — |
| 31 Jul 2026 · Q1 FY27 results, new CFO appointed, Sulcus acquisition | management changes | medium | — | — |
| 31 Jul 2026 · Board approves Q1 results, new CFO, pharma subsidiary acquisition | management changes | high | — | — |
| 30 Jul 2026 · Revised SAST disclosure - pledged holding corrected to 5.11% after stock split error | ownership changes | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 14.3 |
| GLOBAL HEALTH LIMITED | 38,972 | 70.0 | 9.78 | 39.4 | 13.9 | 13.5 | — | 23.7 |
| NARAYANA HRUDAYALAYA LTD. | 38,213 | 46.5 | 8.42 | 25.4 | 17.8 | 9.2 | 25.0 | 18.8 |
| KRISHNA INST OF MED SCI L | 32,235 | 150.5 | 12.60 | 43.4 | 9.5 | 5.1 | 24.0 | 20.3 |
| DR AGARWALS HEALTH CARE L | 16,043 | 107.9 | 7.57 | 26.2 | 7.9 | 7.1 | — | 28.8 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 9.8 | 47.3 | 3 of 30 | 93% |
| P/B | 1.2 | 6.2 | 2 of 24 | 96% |
| ROCE | 12.3 | 10.9 | 12 of 30 | 62% |
| ROE | 12.9 | 11.8 | 11 of 24 | 57% |
| Debt / Equity | 0.3 | 0.2 | 18 of 24 | 26% |
| EBITDA margin | 21.9 | 22.0 | 13 of 24 | 48% |
| Revenue growth | 18.2 | 20.2 | 13 of 23 | 46% |
| Profit growth | (14.5) | 8.1 | 18 of 21 | 15% |
| Market cap | 1831 | 2415 | 17 of 30 | 45% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.